Minimal residual disease as a target for liquid biopsy in patients with solid tumours
Nature Reviews Clinical Oncology,
Год журнала:
2024,
Номер
22(1), С. 65 - 77
Опубликована: Ноя. 28, 2024
Язык: Английский
Personalized ctDNA for Monitoring Disease Status in Head and Neck Squamous Cell Carcinoma
Clinical Cancer Research,
Год журнала:
2024,
Номер
30(15), С. 3329 - 3336
Опубликована: Июнь 2, 2024
Many
patients
with
locoregionally
advanced
human
papillomavirus-negative
head
and
neck
squamous
cell
carcinoma
(HNSCC)
relapse.
ctDNA
has
the
potential
to
identify
minimal
residual
disease,
but
its
clinical
utility
for
virus-negative
HNSCC
is
not
well
understood.
Язык: Английский
Emerging Proximal Liquid Biopsy Approaches for Detecting Residual Disease and Predicting Recurrence in Head and Neck Cancer: A Review and Proposal of Novel Liquid Staging
Head & Neck,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 21, 2025
Head
and
neck
squamous
cell
carcinoma
remains
challenging
due
to
high
recurrence
rates
poor
survival
outcomes.
Developing
precise
technologies
for
disease
burden
assessment,
treatment
response,
minimal
residual
(MRD)
surveillance
is
crucial
improving
prognosis.
This
review
explores
the
potential
of
liquid
biopsy
MRD
detection.
A
novel
TNM
(LiTNM)
staging
system
introduced,
integrating
biomarkers
from
saliva,
surgical
drain
lymphatic
fluid
(SLF),
peripheral
blood.
Proximal
biopsies,
particularly
saliva
SLF,
offer
advantages
their
proximity
tumor
microenvironment.
Saliva
demonstrates
sensitivity
in
HPV-associated
oropharyngeal
cancers,
while
SLF
holds
identifying
early
postoperative
recurrence.
Despite
these
advancements,
standardization
validation
remain
challenges.
Liquid
approaches
show
promise
monitoring,
yet
clinical
implementation
stages.
The
proposed
LiTNM
could
complement
by
providing
a
molecular
framework
risk
stratification.
However,
rigorous
prospective
studies
are
necessary
validate
its
utility
facilitate
adoption.
Язык: Английский
Circulating tumor DNA in human papillomavirus-associated oropharyngeal cancer management: A systematic review
Oral Oncology,
Год журнала:
2025,
Номер
164, С. 107262 - 107262
Опубликована: Апрель 1, 2025
Язык: Английский
Precision Medicine Beyond Genomics
Опубликована: Янв. 1, 2025
Abstract
Precision
oncology
based
on
specific
genomic
alterations
has
become
a
standard
in
the
management
of
some
tumours.
Different
studies
(NCI-MATCH,
TAPUR,
DRUP,
or
MyPathway)
have
used
broader
approach,
testing
multiple
genes
at
same
time
and
assigning
targeted
therapies
basket
trials.
These
showed
encouraging
results
supporting
potential
use
next-generation
sequencing
precision
oncology.
However,
application
head
neck
cancer
(except
for
salivary
gland
tumours)
is
still
limited.
The
field
moving
quickly
into
other
approaches
such
as
whole
genome
transcriptome
analysis.
Transcriptome
analyses
successfully
helped
treatment
decisions
patients
within
prospective
(WINTHER,
POG).
In
cancer,
gene
expression
signatures
evaluating
hypoxia
predicting
anti-epidermal
growth
factor
receptor
(EGFR)
therapy
response,
been
explored.
As
immunotherapy
squamous
carcinoma,
ribonucleic
acid
(RNA)-based
immune
proposed
to
select
those
with
higher
probabilities
response.
All
these
are
bulk
transcriptomics.
Nevertheless,
understanding
role
each
cell
its
spatial
configuration
could
be
useful
this
sense,
single-cell
RNA
provide
better
different
populations
their
activities
potentially
predict
Other
immune-related
biomarkers
T-cell
characteristics
an
improved
insight
resistance
cancer.
Non-coding
analysis
may
contribute
mechanisms
sensitivity
drugs
aid
discovering
new
therapeutic
targets.
most
current
medicine
rely
tumour
tissue.
This
limitation
applicability
due
tumor
heterogeneity
need
biopsies.
Easy-to-access
circulating
deoxyribonucleic
(ctDNA)
overcome
both
limitations
well
more
dynamic
overview
disease.
Further
molecular
biology
microenvironment
including
multi-institution
collaborative
initiatives
needed
translate
findings
our
clinical
practice.
Язык: Английский
Circulating tumor DNA in head and neck squamous cell carcinoma—current status and future prospects
Academia oncology.,
Год журнала:
2024,
Номер
1(2)
Опубликована: Дек. 19, 2024
Squamous
cell
carcinoma
(SCC)
is
the
most
common
malignancy
of
head
and
neck.
Stagnating
survival
rates
in
recent
decades,
despite
advances
treatment
paradigms,
surveillance
technologies,
multidisciplinary
care,
leave
clinicians
with
a
need
for
better
options
screening,
risk-stratifying,
monitoring
patients.
A
growing
proportion
patients
HPV-associated
SCC
have
improved
outcomes
but
continue
to
heterogenous
response
treatment.
Advances
platforms
assays
measuring
circulating
tumor
DNA
offer
an
opportunity
monitor
disease
status
at
molecular
level
both
virally
mediated
traditional
risk-factor-driven
This
overview
will
discuss
experimental,
clinically
used,
commercially
available
liquid
biopsy
their
applications
neck
malignancies.
Язык: Английский